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Simple Summary: It is important to address the influence of 21-gene Recurrence Score (RS) on
chemotherapy decision-making stratified by clinical risk in patients with hormone receptor (HR)-
positive/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. Our study
presented that the application of the 21-gene RS assay significantly reduced the chemotherapy rate in
patients with high clinical risk. Meanwhile, there was no significant difference in the chemotherapy
rate according to the implementation of the 21-gene RS assay in those with low clinical risk. Fur-
thermore, we observed no difference in prognosis according to the application of 21-gene RS for
either clinical risk. These results suggest that the 21-gene RS could be considered more positively in
HR+/HER2- patients with high clinical risk to reduce chemotherapy rates without increasing the
occurrence of relapse.
Abstract: We assessed the impact of 21-gene Recurrence Score (RS) assay on chemotherapy decision-
making according to binary clinical risk stratification in patients with hormone receptor (HR)-
positive/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. We included
patients with tumors measuring 1–5 cm, N0-1, and HR+/HER2- breast cancer who underwent surgery
followed by adjuvant treatment. The clinical risk was determined by a modified version of Adjuvant!
Online. We performed propensity score matching (PSM) according to the application of 21-gene
RS separately in the low and high clinical risk groups. Before PSM, 342 (39.0%) of 878 patients
were classified as having high clinical risk. In the high clinical risk group, 21-gene RS showed a
significantly reduced chemotherapy rate of 39.3%, without increasing the recurrence. After PSM,
the 21-gene RS application significantly reduced chemotherapy rate by 34.0% in 200 patients with
high clinical risk (21-gene RS application, 32.0% vs. no 21-gene RS application, 66.0%, p < 0.001).
There was also no significant difference in RFS according to 21-gene RS status in the high clinical risk
group (log-rank test, p = 0.467). These results support the usefulness of the 21-gene RS to reduce the
chemotherapy rate without adversely affecting prognosis in a high clinical risk group.
Keywords: breast neoplasms; adjuvant treatment; 21-gene recurrence score; chemotherapy;
clinical risk
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1. Introduction
The 21-gene recurrence score (RS) assay (Oncotype DX, Genomic Heal, Redwood City,
CA, USA) is one of the most frequently used commercially available gene-expression assays
in breast cancer [1,2]. The 21-gene RS based on Oncotype DX assay was initially developed
to quantify the likelihood of distant recurrence in women with hormone receptor (HR)-
positive/human epidermal growth factor receptor 2 (HER2)-negative, node-negative breast
cancer, with a high RS on a scale of 0 to 100 indicating a higher risk of distant recurrence [3,4].
Although the adjuvant chemotherapy reduced the risk of distant recurrence [5–7], there is a
concern that the chemotherapy is unnecessary in the majority of patients with HR-positive,
HER2-negative breast cancer. The predictive value of the 21-gene RS for chemotherapy
benefit in women with ER-positive, HER2-negative breast cancer has been validated
in several prospective clinical trials, including the National Surgical Adjuvant Breast
and Bowel Project B-20 trial, Southwest Oncology Group (SWOG)-8814 trial, and Trial
Assigning Individualized Options for Treatment (TAILORx) [8–11]. The chemotherapy
benefit was observed when the 21-gene RS was high, whether a high 21-gene RS was
defined as 31 or higher, or 26 or higher. Based on these results, the National Comprehensive
Cancer Network guidelines recommend strong consideration of the 21-gene RS assay to
determine the adjuvant chemotherapy in patients with tumor size > 0.5 cm, N0, and HR-
positive/HER2-negative breast cancer [12]. Consequently, the use of the 21-gene RS has
led to a decline in the chemotherapy rate sparing serious toxicities for HR-positive, HER-
negative breast cancer in clinical practice [13–16].
The TAILORx trial was designed to address whether the adjuvant chemotherapy is
beneficial for patients with HR+/HER2-, node-negative breast cancer with a midrange RS
of 11 to 25, and revealed that adjuvant endocrine therapy alone was not inferior compared
to adjuvant chemotherapy plus endocrine therapy [6]. Moreover, the results of a secondary
analysis of the TAILORx suggested that the integration of the 21-gene RS and clinical risk
provided more accurate information on the prognosis and the chemotherapy benefit of
individual patients [17]. However, whether the application of 21-gene RS has an advantage
in terms of reduction for adjuvant chemotherapy without adverse survival outcomes
stratified by clinical risk has not yet been reported.
This study investigated the chemotherapy rates in the patient groups stratified by
clinical risk according to 21-gene RS use. We also analyzed the impact of 21-gene RS on
survival outcomes according to clinical risk.
2. Materials and Methods
2.1. Study Population
Following the Good Clinical Practice guidelines and the principles of the Declaration
of Helsinki, our study was approved by the Institutional Review Board at Gangnam
Severance Hospital, Yonsei University, Seoul, Republic of Korea (IRB no. 3-2021-0042),
which waived the requirement for informed consent due to the retrospective study design.
The medical records of patients with breast cancer who underwent breast surgery fol-
lowed by adjuvant treatment at Gangnam Severance Hospital between January 2014 and De-
cember 2018 were reviewed. We identified 878 patients with tumor size of 1–5 cm, pathologic
node stage 0–1, HR-positive, HER2-negative breast cancer (Figure 1). The available clinico-
pathologic data included age, type of surgery, adjuvant treatment including chemotherapy
and endocrine therapy, survival, ER status, progesterone receptor (PR) status, HER2 status,
Ki-67 levels, histologic type, histologic grade (HG), lymphovascular invasion (LVI) status,
pathologic stage, and 21-gene RS. The clinical risk was assessed using the Adjuvant! Algo-
rithm as described in the MINDACT trial [18,19]. We classified the clinical risk as low or
high based on the tumor size, nodal metastasis, and HG. Briefly, in N0 patients, the clinical
risk was defined as low if the tumor was ≤3 cm in diameter and had a low HG, ≤2 cm in
diameter and had an intermediate HG, or ≤1 cm in diameter and had a high HG. In N1
patients, the clinical risk was defined as low if the tumor was ≤2 cm in diameter and had a
low HG. The clinical risk was defined as high if the low-risk criteria were not met.
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Figure 1. Study flowchart.
Oncotype DX 21-gene RS assays were not routinely performed in our institution
because they are not covered by insurance. The clinicians discussed the use of the
21-gene RS with the patient based on the patient’s clinicopathologic risk factors as well
as their personal preferences. Previous studies, which predicted 21-gene RS results with
clinicopathologic data, reported that the age, tumor size, HG, PR, LVI, and Ki-67 were re-
lated to the RS [20–22]. Based on these, the Oncotype DX assay was frequently omitted in
patients whose clinicopathologic features were either mostly favorable or poor because their
21-gene RS was strongly expected to be l w or high. In contrast, the clinicians generally
recomme ded the application of the 21-gene RS assay to patients with intermediate or mixed
clinicopathologic data. Consequently, 318 (36.2%) patients underwent 21-gene RS testing.
2.2. Immunohistochemistry
In our immunohistochemistry study, formalin-fixed, paraffin-embedded tissue sec-
tions obtained from surgical specimens were stained using appropriate antibodies specific
for four markers: ER (1:100 dilution, clone 6F11; Novocastra, Newcastle upon Tyne, UK),
PR (clone 16; Novocastra, UK), HER2 (4B5 rabbit onoclonal antibody; Ventana Medical
Systems, Tucson, AZ, USA), and Ki-67 (MIB-1; Dako, Glo trup, Denmark). According to
the modified Allred system, ER and PR positivity were defined as Allred scores of 3–8,
while negativity was defined as Allred scores of 0 and 2, respectively. We considered Allred
scores of 7–8 to indicate high expression levels. HER2 status was defined as positive for
scores of 3+ and negative for scores of 0 or 1+. Tumors with scores of 2+ were sent for
fluorescent in situ hybridization analysis according to the suppliers’ protocols (PathVysion
kit; Vysis, Downers Grove, IL, USA, or HER2 inform; Ventana). We defined Ki-67 levels
≥14% as high.
2.3. 21-Gene RS Assay
The 21-gene RS assay (Oncotype DX, Genomic Health, Redwood City, CA, USA)
is based on reverse transcriptase-polymerase chain reaction (RT-PCR) that can be per-
formed on the RNA isolated from formalin-fixed paraffin-embedded (FFPE) tissue [3].
After reviewing the hematoxylin and eosin-stained slides to determine whether sufficient
invasive breast cancer was present and whether manual microdissection was indicated,
RNA extraction from the unstained sections and the 21-gene RS assay was performed
by Genomic Health (Redwood City, CA, USA). This assay evaluates the expression of
16 tumor-associated genes (ER, PGR, BCL2, SCUBE2, GRB7, HER2, Ki-67, STK15, Sur-
vivin, CCNB1, MYBL2, MMP11, CTSL2, GSTM1, CD68, BAG1) and 5 reference genes
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(ACTB, GAPDH, RPLPO, GUS, TFRC) by using RT-PCR. Based on the expression levels of
21-genes, an algorithm was designed to compute a 21-gene RS for each sample. Quantita-
tive single-gene scores for ER and PR mRNA expression, determined via an RT-PCR, were
also provided within the final assay report by Genomic Health.
2.4. Statistical Analysis
Categorical variables were compared by chi-square tests. The chemotherapy rates
according to the clinical risk were analyzed by chi-square or Fisher’s exact tests. Binary
logistic regression analysis was performed to identify independent factors associated
with a reduced chemotherapy rate. Variables with p < 0.10 in univariable analysis were
included in the multivariable analysis. We performed an individual propensity score
matching (PSM) analysis in which randomly selected patients with 21-gene RS were
paired with comparable patients without 21-gene RS. The one case per one control was
selected based on age (≤50 vs. >50 years), histologic type (invasive ductal carcinoma vs.
invasive lobular carcinoma vs. others), histologic grade (I or II vs. III), ER (Allred score
0–6 vs. 7–8), PR (Allred score 0–6 vs. 7–8), Ki-67 (<14% vs. ≥14%), pathologic T stage (1 vs. 2),
and pathologic n stage (0 vs. 1). Recurrence-free survival (RFS) was measured as the period
from the date of breast cancer surgery to first breast cancer recurrence, including loco-regional
and distant recurrences. The Kaplan–Meier method with a log-rank test was used to calculate
the RFS and compare the results between groups. All analyses were performed using IBM
SPSS Statistics for Windows, version 23.0 (IBM Corp.; Armonk, NY, USA) and SAS (version
9.3, SAS Inc., Cary, NC, USA). The statistical significance was defined as p < 0.05.
3. Results
3.1. Baseline Characteristics
The median age of all patients was 52 years (range, 25–87). Among all patients,
536 (61.0%) and 342 (39.0%) were at low and high clinical risk, respectively (Figure 1).
As expected, patients with high clinical risk had more poor prognostic factors such as high
HG, Ki-67, pathologic T stage, pathologic n stage, LVI, and low PR expression compared to
those in patients with low clinical risk. The chemotherapy rate (52.6% vs. 13.2%, p < 0.001),
and implementation of 21-gene RS (42.1% vs. 32.5%, p = 0.004) were significantly higher in
patients with high clinical risk. Moreover, patients with high clinical risk and 21-gene RS
had favorable clinicopathologic factors, while the reverse trend was observed in patients
with low clinical risk (Table S1). Meanwhile, the distributions of categorical 21-gene RS did
not differ according to clinical risk (Figure S1); the results were consistent using different
21-gene RS cutoffs used in clinical trials; namely: low (<18 or <11), intermediate (18–30 or
11–25), and high (≥31 or >25).
To minimize the baseline confounders affecting the chemotherapy rate, a one-to-one
PSM between patients with or without 21-gene RS was carried out separately in the low
and high clinical risk groups. Of 464 patients (median age, 52 years; range, 25–87) in the
PSM cohort, 264 (56.9%) showed low clinical risk, while 200 (43.1%) showed high clinical
risk. After PSM, all variables were well balanced according to the implementation of
21-gene RS in both clinical risk groups (Table 1).
Table 1. Baseline characteristics according to clinical risk stratified by 21-gene RS use in the propensity-score matched cohort.
Characteristics
















(n = 200) p-Value
Age (median) 50 50.5 50 0.405 49 55 51 0.198
Age (range) 25-81 32-86 25-86 27-87 33-75 27-87
Age (y) 0.902 0.777
≤50 70 (53.0%) 71 (53.8%) 141 (53.4%) 49 (49.0%) 47 (47.0%) 96 (48.0%)
>50 62 (47.0%) 61 (46.2%) 123 (46.6%) 51 (51.0%) 53 (53.0%) 104 (52.0%)
Histologic type >0.999 >0.999
IDC 128 (97.0%) 127 (96.2%) 255 (96.6%) 90 (90.0%) 89 (89.0%) 179 (89.5%)
ILC 2 (1.5%) 2 (1.5%) 4 (1.5%) 8 (8.0%) 9 (9.0%) 17 (8.5%)
Others * 2 (1.5%) 3 (2.3%) 5 (1.9%) 2 (2.0%) 2 (2.0%) 4 (2.0%)
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(n = 200) p-Value
ER, Allred 0.848 0.010
7–8 117 (88.6%) 116 (87.9%) 233 (88.3%) 90 (90.0%) 96 (96.0%) 186 (93.0%)
0–6 15 (11.4%) 16 (12.1%) 31 (11.7%) 10 (10.0%) 4 (4.0%) 14 (7.0%)
PR, Allred 0.318 0.671
7–8 73 (55.3%) 81 (61.4%) 154 (58.3%) 52 (52.0%) 55 (55.0%) 107 (53.5%)
0–6 59 (44.7%) 51 (38.6%) 110 (41.7%) 48 (48.0%) 45 (45.0%) 93 (46.5%)
Histologic grade >0.999 0.732
1 or 2 132 (100%) 132 (100%) 264 (100%) 77 (77.0%) 79 (79.0%) 156 (78.0%)
3 0 0 0 23 (23.0%) 21 (21.0%) 44 (22.0%)
LVI † >0.999 0.884
Yes 12 (9.1%) 12 (9.1%) 24 (9.1%) 37 (37.0%) 38 (38.0%) 75 (37.5%)
No 120 (90.9%) 120 (90.9%) 240 (90.9%) 63 (63.0%) 62 (62.0%) 125 (62.5%)
Ki-67 0.295 0.768
≥14 32 (24.2%) 25 (18.9%) 57 (21.6%) 65 (65.0%) 63 (63.0%) 128 (64.0%)
<14 100 (75.8%) 107 (81.1%) 207 (78.4%) 35 (35.0%) 37 (37.0%) 72 (36.0%)
T stage >0.999 0.556
1 129 (97.7%) 128 (97.0%) 257 (97.3%) 38 (38.0%) 34 (34.0%) 72 (36.0%)
2 3 (2.3%) 4 (3.0%) 7 (2.7%) 62 (62.0%) 66 (66.0%) 128 (64.0%)
n stage >0.999 0.888
0 122 (92.4%) 122 (92.4%) 244 (92.4%) 52 (52.0%) 51 (51.0%) 103 (51.5%)
1 10 (7.6%) 10 (7.6%) 20 (7.6%) 48 (48.0%) 49 (49.0%) 97 (48.5%)
* Others (n = 9) included mucinous (n = 5), tubular (n = 2), and papillary (n = 2) breast cancers. † Missing values. Abbreviations: RS,
recurrence score; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; ER, estrogen receptor; PR, progesterone receptor; LVI,
lymphovascular invasion.
3.2. Chemotherapy Rates
Among the 536 patients with low clinical risk, 41 of 362 (11.3%) without 21-gene RS
and 30 of 174 (17.2%) with 21-gene RS received chemotherapy (p = 0.059). Among patients
with node-negative and low clinical risk, 27 of 344 (7.8%) without 21-gene RS and 30 of
161 (18.6%) with 21-gene RS received chemotherapy (p < 0.001). Among patients with
node-positive and low clinical risk, 14 of 18 (77.8%) without 21-gene RS and none of the
patients with 21-gene RS received chemotherapy (p < 0.001, Figure 2A). Meanwhile, among
the 342 patients with high clinical risk, 137 of 198 (69.2%) without 21-gene RS and 43 of
144 (29.9%) with 21-gene RS received chemotherapy (p < 0.001). Among patients with the
node-negative disease and high clinical risk, 51 of 91 (56.0%) without 21-gene RS and 30
of 91 (33.0%) with 21-gene RS received chemotherapy (p = 0.002). Among patients with
node-positive disease and high clinical risk, 86 of 107 (80.4%) without 21-gene RS and
13 of 53 (24.5%) with 21-gene RS received chemotherapy (p < 0.001, Figure 2B). In the
multivariable analysis, the implementation of the 21-gene RS was an independent factor
associated with a reduced chemotherapy rate in the high clinical risk group (odds ratio
(OR) 0.196; 95% confidence interval (CI), 0.115–0.334; p < 0.001, Table 2). Furthermore, the
implementation of 21-gene RS was significantly associated with a reduced chemotherapy
rate in both N0 (OR 0.357; 95% CI, 0.176–0.724; p = 0.004) and N1 (OR 0.085; 95% CIs,
0.036–0.200; p < 0.001) disease.
After PSM, the chemotherapy rates did not differ significantly according to 21-gene
RS status in women with low clinical risk (15.2% (20 of 132) in patients without 21-gene RS
vs. 13.6% (18 of 132) in patients with 21-gene RS, p = 0.726) and those with low clinical risk
and node-negative disease (11.5% (14 of 122)in patients without 21-gene RS vs. 14.8% (18
of 122) in patients with 21-gene RS, p = 0.448, Figure 3A). Otherwise, use of the 21-gene RS
was associated with significantly reduced chemotherapy rates in women with low clinical
risk and node-positive disease (60.0% (6 of 10)in patients without 21-gene RS vs. none in
patients with 21-gene RS, p = 0.011). Likewise, use of the 21-gene RS was associated with
a significantly decreased chemotherapy rate in women with high clinical risk (66.0% (66
of 100) in patients without 21-gene RS vs. 32.0% (32 of 100) in patients with 21-gene RS,
p < 0.001), high clinical risk and node-negative disease (60.8% (31 of 51) in patients without
21-gene RS vs. 38.5% (20 of 52) in patients with 21-gene RS, p = 0.023), and high clinical
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risk and node-positive disease (71.4% (35 of 49) in patients without 21-gene RS vs. 25.0%
(12 of 48) in patients with 21-gene RS, p < 0.001, Figure 3B).
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Table 2. Adjusted odds ratios (ORs) and 95% confidential intervals (CIs) of 21-gene RS for the implementation of chemother-
apy in patients with high clinical risk among the entire cohort.
Multivariable Analysis
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Figure 3. Chemotherapy rates according to the application of the 21-gene Recurrence Score (RS) assay in the propensity-
Scheme 21-gene RS assay stratified by clinical risk in patients with (A) low clinical risk and (B) high clinical risk. Chi-
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3.3. Clinical Outcomes
In the entire cohort, there were 14 recurrence events and no deaths during the median
follow-up of 42 months (range, 1–83 months). There was no significant difference in RFS
according to 21-gene RS status (log-rank test, p = 0.363; Figure 4A). In addition, RFS did
not differ according to 21-gene RS status in both groups stratified by clinical risk (p = 0.489
in the low clinical risk group and p = 0.736 in the high clinical risk group, Figure 4B,C).
In the PSM cohort, there were eight recurrence events and no deaths during the median
follow-up of 45 months (range, 1–83 months). Likewise, there was no significant difference
in RFS according to 21-gene RS status (log-rank test, p = 0.850 in the PSM cohort, log-rank
test, p = 0.583 in the PSM cohort with low clinical risk, and p = 0.467 in the PSM cohort with
high clinical risk; Figure 4D,F).
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4. Discussion
Before the era of genomic assays, aggressive chemotherapy was considered for patients
at a high clinical risk. However, within node-positive, HR+ breast cancer, several multigene
assays revealed that tumors with favorable genomic profiles showed a good prognosis
despite a high clinical risk [9,23]. Thus, many investigators wondered assessed whether
chemotherapy could be spared in patients with discordant clinical and genomic risk
profiles. Concerning this issue, the MINDACT investigators reported no substantial benefit
of chemotherapy in patients with clinical high/genomic low risk in terms of distant
RFS [12,19]. Moreover, secondary analysis of the TAILOR-X trial showed that the addition
of chemotherapy was associated with lower rates of distant recurrence among women with
RS of 21–25 and low clinical risk [11].
In this context, it is important to address the influence of 21-gene RS on chemotherapy
decision-making according to clinical risk stratification. First, we speculated that 21-gene
RS is more helpful in patients with high clinical risk. Although there was no significant
difference in chemotherapy rates according to the application of the 21-gene RS in the low
clinical risk group, use of the 21-gene RS reduced the chemotherapy rate by approximately
30–40% in the high clinical risk group. Furthermore, the results of the multivariable
analysis showed that the application of 21-gene RS was an independent factor for reduced
chemotherapy rate in patients at high clinical risk. However, the concerns remain that
significant differences in clinicopathologic factors associated with prognosis according
to the 21-gene RS in each of the low and high clinical risk groups may influence the
chemotherapy rate. Thus, we performed PSM analysis, with similar results: the application
of the 21-gene RS reduced the chemotherapy rate by 34% in patients at high clinical risk.
Moreover, we also observed no difference in survival outcomes according to the application
of 21-gene RS for either clinical risk group. These results suggest that the 21-gene RS could
be considered more positively in patients with high clinical risk to reduce chemotherapy
rates without increasing the occurrence of relapse.
The trend of reduced chemotherapy rate with the application of the 21-gene RS was
more pronounced in N1 patients than N0 patients, regardless of clinical risk. This may
occur because N1 patients are strongly recommended to receive chemotherapy unless the
21-gene RS is performed. Accumulating evidence indicates that the 21-gene RS can predict
the risk of recurrence and chemotherapy benefit even in N1 patients. N1 patients with
RS < 18 who received only endocrine therapy showed comparable 9-year risks of distant
recurrence to those with the node-negative disease in the transATAC trial [24]. Similarly,
the Surveillance, Epidemiology, and End Results (SEER) and Clalit Health Services registry
studies consistently showed favorable 5-year outcomes in N1 patients with RS <18 treated
largely without adjuvant chemotherapy [25,26]. Moreover, a retrospective analysis of the
SWOG S8814 trial revealed no benefit of chemotherapy in N1 patients with RS < 18 [9]. The
RxPONDER trial found that postmenopausal women with N1 and RS ≤ 25 could safely
avoid chemotherapy [27]. Together, these data suggest that it is worth applying the 21-gene
RS in N1 patients to decrease overtreatment, particularly in postmenopausal women.
In addition, the chemotherapy rates also did not differ according to the use of the
21-gene RS in the low clinical risk group after PSM. This finding could raise another issue
regarding the necessity of applying the 21-gene RS assay to determine chemotherapy
in patients at low clinical risk. However, it is well established that a high 21-gene RS
could predict the clinical benefit from chemotherapy: in the TAILOR-X study, the 21-gene
RS identified patients with clinical low risk who benefited from chemotherapy. Further
studies integrating clinical and genomic risk profiles with long-term follow are warranted
to address the role of the 21-gene RS in patients with low clinical risk.
Our study has a major limitation inherent in retrospective analysis from a single
institution with a small proportion of patients who received Oncotype DX assay. In addition,
the median follow-up period was relatively short (42 months and 45 months in the PSM
cohort), considering that disease-related events occur steadily 5 years after diagnosis in
HR+/HER2- breast cancer [28]. Few studies have assessed the survival benefit according
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to the implementation of the 21-gene RS. To our best knowledge, only one recent study
analyzing SEER registry data reported that the application of the 21-gene RS was associated
with better breast cancer-specific and overall survivals [29]. However, that study also
has limitations, including a median follow-up period of only 36 months and the fact that
chemotherapy tended to be underreported in SEER data [30]. Another limitation of the
present study was that the chemotherapy decision in our cohort may differ from those
made in clinical practice in the future because most patients in our study received treatment
before the results of the TAILORx and RxPONDER trials were presented. Lastly, in that era,
the guideline for adjuvant treatment was unclear in patients with intermediate RS; thus,
the adjuvant treatments may have differed depending on the physicians, which may have
affected the clinical outcomes. Therefore, further studies with accurate data collection for
adjuvant treatment guided by 21-gene RS and a sufficient follow-up period are needed to
clarify whether the application of 21-gene RS influences survival benefits.
5. Conclusions
In summary, this is the first study to analyze the usefulness of the 21-gene RS according
to clinical risk in the subset of patients with tumor size 1–5 cm, N0-1, HR+/HER2- breast
cancer, in terms of chemotherapy rate and survival. The application of the 21-gene RS
reduced chemotherapy rates, particularly in patients with high clinical risk. In contrast,
it did not alter the chemotherapy rate in patients with low clinical risk in the case-matched
cohort. Furthermore, the survival outcomes according to implementation of the 21-gene
RS did not differ, even in patients at high clinical risk. These data suggest that the 21-gene
RS should be considered positively to reduce overtreatment without adverse prognosis in
patients with high clinical risk. For the patients with low clinical risk, further studies with
long-term follow-up data are warranted to address the role of the 21-gene RS, which could
offer chemotherapy for patients with high genomic risk.
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